Published in Antimicrob Agents Chemother on February 01, 1992
Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol (2010) 2.11
Assessment of a fluoroquinolone, three beta-lactams, two aminoglycosides, and a cycline in treatment of murine Yersinia pestis infection. Antimicrob Agents Chemother (1994) 1.52
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother (1994) 1.51
Bioequivalence of oral and intravenous ofloxacin after multiple-dose administration to healthy male volunteers. Antimicrob Agents Chemother (1993) 1.22
Adverse events in healthy individuals and MDR-TB contacts treated with anti-tuberculosis drugs potentially effective for preventing development of MDR-TB: a systematic review. PLoS One (2013) 0.88
Effect of inflammation on intraocular penetration of intravenous ofloxacin in albino rabbits. Antimicrob Agents Chemother (1995) 0.84
Safety evaluation of a new formulation of intravenous ofloxacin. Drugs (1995) 0.75
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm (1978) 10.01
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci (1976) 4.75
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1987) 2.95
Pharmacokinetics of ofloxacin. An overview. Am J Med (1989) 1.58
Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers. Antimicrob Agents Chemother (1991) 1.33
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet (1986) 2.07
Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother (1983) 1.86
Intravenous iron supplementation in end-stage renal disease patients. Am J Kidney Dis (1999) 1.57
Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis (1999) 1.54
The metabolism of indomethacin in man. J Pharmacol Exp Ther (1972) 1.44
Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. Perit Dial Int (1991) 1.42
Epidemic cholera in the Amazon: the challenge of preventing death. Am J Trop Med Hyg (1993) 1.35
Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther (1985) 1.34
Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther (1997) 1.33
Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther (1990) 1.32
Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients. Am J Med (1987) 1.30
Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother (1990) 1.28
Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics (2010) 1.23
Systemic absorption of oral vancomycin in patients with renal insufficiency and antibiotic-associated colitis. Am J Kidney Dis (1987) 1.23
Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens (1985) 1.18
Human liver protein map: a reference database established by microsequencing and gel comparison. Electrophoresis (1992) 1.18
The 1918-1920 influenza pandemic in Peru. Vaccine (2011) 1.17
Initial clinical experience with a new peripheral vasodilator, PR-G-138-Cl, in hypertensive patients. Eur J Clin Pharmacol (1975) 1.17
A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis (1995) 1.14
Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos (1991) 1.13
A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother (1998) 1.10
Topological properties of two cubic phases of a phospholipid:cholesterol:diacylglycerol aqueous system and their possible implications in the phospholipase C-induced liposome fusion. FEBS Lett (1995) 1.10
Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet (1982) 1.09
Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther (1990) 1.07
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J Am Soc Nephrol (1998) 1.06
Cubic phases of lipid-containing systems. Elements of a theory and biological connotations. J Mol Biol (1993) 1.06
Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med (1993) 1.06
Using a knowledge, attitudes and practices survey to supplement findings of an outbreak investigation: cholera prevention measures during the 1991 epidemic in Peru. Int J Epidemiol (1996) 1.05
Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets. Thromb Res (1986) 1.05
Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos (1975) 1.05
Effects of high resistance training in patients with myotonic dystrophy. Scand J Rehabil Med (1999) 1.04
Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. Shock (2000) 1.04
Transdermal administration of clonidine for treatment of high BP. Arch Intern Med (1984) 1.03
Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial. Crit Care Med (1995) 1.03
Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm (1976) 1.03
A study of hypertension in the inner city. A student hypertension survey. Am Heart J (1973) 1.02
Comparative metabolism of aspartame in experimental animals and humans. J Toxicol Environ Health (1976) 1.02
Epidemic cholera in the Amazon: the role of produce in disease risk and prevention. J Infect Dis (1994) 1.02
Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc (1986) 1.02
Cefazolin as empiric therapy in hemodialysis-related infections: efficacy and blood concentrations. Am J Kidney Dis (1998) 1.02
Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood (1990) 1.01
A review of disorders of water homeostasis in psychiatric patients. Psychosomatics (1991) 1.00
Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol (1982) 0.99
Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1984) 0.99
Metabolism of a new hypolipidemic agent, 2-acetamidoethyl(p-chlorophenyl) (m-trifluoromethylphenoxy)-acetate (halofenate) in the rat, dog, rhesus monkey and man. J Pharmacol Exp Ther (1971) 0.99
Production of hapten-specific T cell hybridomas and their use to study the effect of ultraviolet B irradiation on the development of contact hypersensitivity. J Immunol (1989) 0.99
Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int (1998) 0.99
Lipid polymorphism: a correction. The structure of the cubic phase of extinction symbol Fd-- consists of two types of disjointed reverse micelles embedded in a three-dimensional hydrocarbon matrix. Biochemistry (1992) 0.99
Cubic phases of lipid-containing systems. A translational diffusion study by fluorescence recovery after photobleaching. J Mol Biol (1993) 0.98
Soil respiration at mean annual temperature predicts annual total across vegetation types and biomes. Biogeosciences (2010) 0.98
A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city. Int J Tuberc Lung Dis (1999) 0.98
Estradiol protects against experimental cardiac transplant atherosclerosis. Transplant Proc (1987) 0.97
Bioavailability of oral dexamethasone. Clin Pharmacol Ther (1975) 0.97
Essential hypertension. Br J Clin Pharmacol (1979) 0.96
Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm (1995) 0.96
Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol (1985) 0.95
Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis (1998) 0.93
Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther (2001) 0.93
Can garlic lower blood pressure? A pilot study. Pharmacotherapy (1993) 0.93
Disposition of vancomycin during hemofiltration. Clin Pharmacol Ther (1986) 0.93
Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl (2012) 0.93
Treating severe metabolic alkalosis. Clin Pharm (1983) 0.92
Antidiarrhoeal activity of Waltheria americana, Commelina coelestis and Alternanthera repens. J Ethnopharmacol (1998) 0.92
In vitro effect of oestradiol on thymidine uptake in pulmonary vascular smooth muscle cell: role of the endothelium. Br J Pharmacol (1992) 0.92
[Hypercoagulability in the nephrotic syndrome of children]. Arch Invest Med (Mex) (1975) 0.91
Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens (1990) 0.91
Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension (1997) 0.90
Total knee replacement in post-traumatic arthritic knees with limitation of flexion. Orthop Traumatol Surg Res (2010) 0.90
Should intravenous immunoglobulin G be first-line treatment for acute thrombotic thrombocytopenic purpura? Case report and review of the literature. Am J Kidney Dis (1991) 0.90
Codeine dosage in renal failure. Clin Pharm (1986) 0.90
Mesangiocapillary glomerulonephritis with dense "deposits" in the basement membranes of the kidney. Clin Nephrol (1976) 0.90
Analgesic efficacy of low-dose ibuprofen in dental extraction pain. Pharmacotherapy (1987) 0.89
Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Clin Pharm (1985) 0.89
Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet (2001) 0.88
Controlled comparison of gentamicin and tobramycin nephrotoxicity. Am J Nephrol (1983) 0.88
Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism. J Pharmacol Exp Ther (1996) 0.88
Coyolosa, a new hypoglycemic from Acrocomia mexicana. Pharm Acta Helv (1997) 0.88
Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol (1987) 0.88
Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother (1990) 0.88
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther (1988) 0.87
An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol (1998) 0.87
Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol (1991) 0.87
Role of the endothelium and arginine peptides on the vaso-motor response of porcine internal mammary artery. Life Sci (1989) 0.87
Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol (1998) 0.86
The efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee. Clin Ther (1997) 0.86
Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium. J Pharmacol Exp Ther (1990) 0.86
Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother (1983) 0.86
Structural criteria for the rational design of selective ligands. 3. Quantitative structure-stability relationship for iron(III) complexation by tris-catecholamide siderophores. Inorg Chem (2001) 0.86
Uricosurics and xanthine oxidase inhibitors: a single-dose assay. Curr Ther Res Clin Exp (1970) 0.85
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med (1993) 0.85
Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol (1987) 0.85
Potentiation of hypoglycemic effect of sulfonylureas by halofenate. N Engl J Med (1975) 0.85
Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing. Antimicrob Agents Chemother (1989) 0.85